SCHEMBL5876465

SCHEMBL5876465

COCC(O)(c1ccccc1)c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.49
MEN1 O00255 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
LMNA P02545 3/20 0.49
ALDH1A1 P00352 1/20 0.49
POLB P06746 1/20 0.49
HTT P42858 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
KCNN4 O15554 3/20 0.43
GAA P10253 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
NR3C2 P08235 1/20 0.39
KIF11 P52732 1/20 0.38
KCNE1 P15382 1/20 0.37
KCNQ1 P51787 1/20 0.37
CHRM3 P20309 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5875787 0.93 KMT2A (0.46) KMT2AMEN1SMN1; SMN2LMNAALDH1A1
SCHEMBL19884937 0.89 SMN1; SMN2 (0.47) KMT2AMEN1SMN1; SMN2ALDH1A1HTT
SCHEMBL23003799 0.82 KMT2A (0.44) KMT2AMEN1SMN1; SMN2LMNAALDH1A1
SCHEMBL11764142 0.79 KMT2A (0.53) KMT2AMEN1SMN1; SMN2LMNAALDH1A1
SCHEMBL9729319 0.79 CHRM3 (0.46) SMN1; SMN2KCNN4NR3C2KIF11CHRM3
SCHEMBL5930993 0.77 KMT2A (0.50) KMT2AMEN1SMN1; SMN2LMNAALDH1A1
SCHEMBL6618203 0.77 HTT (0.55) KMT2AMEN1SMN1; SMN2LMNAPOLB
SCHEMBL5876419 0.77 HTT (0.55) KMT2AMEN1SMN1; SMN2LMNAPOLB
SCHEMBL6618200 0.77 HTT (0.55) KMT2AMEN1SMN1; SMN2LMNAPOLB
SCHEMBL3205224 0.73 ALOX15 (0.43) KMT2ASMN1; SMN2ALDH1A1KCNN4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed
EP-1414805-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY Aventis Pharma S.A. (FR) 2004-05-06 EP disclosed
WO-2003011833-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY AVENTIS PHARMA S.A. (FR) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT KMT2A 2326/4885MEN1 548/4885SMN1; SMN2 4244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.